Dataset Information

Alignment of multiple metabolomics LC-MS datasets from disparate diseases to reveal fever-associated metabolites

ABSTRACT:

Acute febrile illnesses are still a major cause of mortality and morbidity globally, particularly in low to middle income countries. The aim of this study was to determine any possible metabolic commonalities of patients infected with disparate pathogens that cause fever. Three liquid chromatography-mass spectrometry (LC-MS) datasets investigating the metabolic effects of malaria, leishmaniasis and Zika virus infection were used. The retention time (RT) drift between the datasets was determined using landmarks obtained from the internal standards generally used in the quality control of the LC-MS experiments. Fitted Gaussian Process models (GPs) were used to perform a high level correction of the RT drift between the experiments, which was followed by standard peakset alignment between the samples with corrected RTs of the three LC-MS datasets. Statistical analysis, annotation and pathway analysis of the integrated peaksets were subsequently performed. Metabolic dysregulation patterns common across the datasets were identified, with kynurenine pathway being the most affected pathway between all three fever-associated datasets.

INSTRUMENT(S): Liquid Chromatography MS - positive - hilic, Liquid Chromatography MS - negative - hilic

SUBMITTER: Ana-Maria Nastase

PROVIDER: MTBLS4895 | MetaboLights | 2023-07-17

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	MTBLS4895	Other
	FILES	Other
	a_MTBLS4895_LC-MS_leishmaniasis_negative_hilic_metabolite_profiling.txt	Txt
	a_MTBLS4895_LC-MS_leishmaniasis_positive_hilic_metabolite_profiling.txt	Txt
	a_MTBLS4895_LC-MS_malaria_negative_hilic_metabolite_profiling.txt	Txt

Items per page:

1 - 5 of 17

Publications

Alignment of multiple metabolomics LC-MS datasets from disparate diseases to reveal fever-associated metabolites.

Năstase Ana-Maria AM Barrett Michael P MP Cárdenas Washington B WB Cordeiro Fernanda Bertuccez FB Zambrano Mildred M Andrade Joyce J Chang Juan J Regato Mary M Carrillo Eugenia E Botana Laura L Moreno Javier J Regnault Clément C Milne Kathryn K Spence Philip J PJ Rowe J Alexandra JA Rogers Simon S

PLoS neglected tropical diseases 20230724 7

PMID: 37486920

Similar Datasets

Project description:Background: Lung cancer (LC) is the leading cause of cancer deaths worldwide with more than 1.7 million deaths each year. Early detection of LC may be crucial to achieve efficient treatment and to increase survival. However, there are limitations to current methods for early detection of LC as they are too invasive and represent potential health hazards, necessitating improved tools to detect LC at an early stage. Blood-based gene expression profiling is an alternative, or additional tool for diagnostic purposes as blood samples are easily available, essentially non-invasive, and can be collected at a low cost. However, as the blood collection method can affect measured gene expression, the aim of this study was to identify mRNAs that are robust biomarkers for LC in blood. How: We sampled blood from 123 LC patients at the St. Olavs university hospital, and 180 controls from two different biobanks sampled on two different blood tubes (PAXgene and Tempus) and used Illumina (HT-12 v4) microarrays to measure whole blood gene expression. We did three analyses: (i) finding relevant gene expression differences between cases and controls, (ii) finding a robust set of genes to be used as a panel to identify presence of LC in blood, and (iii) identifying differences between patients with different pathological traits such as stage and histology. We collected phenotype data from questionnaires and hospital medical records, and evaluated the potential effects of CRP, tumour size, gender, and smoking habits. Results: By comparing cases and controls sampled on the same RNA sampling system (training set), we identified 355 significant genes (Bonferroni adjusted p < 0.05) with biological relevance. When evaluating these on our test set comprising of the same cases as used in the training set but analysed against controls from a different biobank sampled on a different RNA sampling system (test set), we found 50 genes that were robust as they were unaffected by either technical issues in sampling systems, biobank differences, gender, or pathological traits such as LC subtype or stadium. These findings were confirmed in three validation sets and the robust list’s diagnostic potential was validated on RNA sequencing data from a new cohort. By analysing the cases separately, we found seven genes distinguishing squamous cell carcinoma (SCC) from other LC subtypes, and six genes distinguishing early from late-stage LC patients. Pathway analyses and a literature survey indicated that the identified genes show biological relevance for cancer development and lung related diseases.